Skip to main
PGNY

Progyny (PGNY) Stock Forecast & Price Target

Progyny (PGNY) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 56%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Progyny is well-positioned with a differentiated benefits management solution and strong client relationships, as indicated by high client retention rates and solid active working relationships. Management is confident in the company's future growth potential, with a focus on both greenfield and brownfield opportunities. With a strong balance sheet, disciplined cost management, and continued investment in new products and solutions, Progyny has potential for growth and value creation for shareholders.

Bears say

Progyny is facing increased competition in the fertility benefits market, with more RFPs being sent by clients currently working with competitors, potentially due to dissatisfaction with the company's value, returns, reporting, and cost management. There may also be a decrease in Progyny Rx revenue per ART cycle, which could impact revenue. Management may not be able to accurately predict the potential cost of breaking out Rx revenues, causing volatility in financials. Additionally, there are downside risks such as elevated attrition levels, utilization pressures, and economic downturns that could negatively impact the company's growth potential and revenue estimates.

Progyny (PGNY) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 56% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Progyny (PGNY) Forecast

Analysts have given Progyny (PGNY) a Buy based on their latest research and market trends.

According to 9 analysts, Progyny (PGNY) has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Progyny (PGNY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.